Spero Therapeutics (SPRO) Other Working Capital Changes (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Other Working Capital Changes came in at -$421000.0 in Q1 2026, down 24.93% YoY from -$560778.7 in Q1 2025, and down 562.64% on a QoQ basis from $91000.0 in Q4 2025.
Spero Therapeutics (SPRO) Other Working Capital Changes (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 9 years of Other Working Capital Changes data on file, last reported at -$421000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 24.93% year-over-year to -$421000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7000.0 (up 105.6% YoY) and the FY2025 annual result came in at $91000.0, up 204.6% from the prior year.
- Other Working Capital Changes fell to -$421000.0 in Q1 2026, from $91000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $10.9 million in Q3 2021 to a low of -$12.6 million in Q4 2025.
- A 5-year average of -$565684.2 and a median of -$113000.0 in 2024 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes jumped 4020.0% — and 2024, when it plunged 7709.09%.
- Tracing SPRO's Other Working Capital Changes over 5 years: stood at $392000.0 in 2022, then slumped by 93.37% to $26000.0 in 2023, then jumped by 3107.69% to $834000.0 in 2024, then tumbled by 89.09% to $91000.0 in 2025, then plunged by 562.64% to -$421000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$421000.0 (Q1 2026), $91000.0 (Q4 2025), and $682000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -654,000.00 |
| Jun 30, 2026 | -654,000.00 |
| Jun 30, 2026 | -654,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Dec 31, 2025 | -12.59 Mn |
| Dec 31, 2025 | -12.59 Mn |
| Dec 31, 2025 | -12.59 Mn |
| Sep 30, 2025 | 616,000.00 |
| Sep 30, 2025 | 616,000.00 |
| Sep 30, 2025 | 616,000.00 |
| Jun 30, 2025 | -253,000.00 |
| Jun 30, 2025 | -253,000.00 |
| Jun 30, 2025 | -253,000.00 |
| Mar 31, 2025 | -363,000.00 |
| Mar 31, 2025 | -363,000.00 |
| Mar 31, 2025 | -363,000.00 |
| Dec 31, 2024 | 37,000.00 |
| Dec 31, 2024 | 37,000.00 |